Precipio, Inc. reports developments from its specialty cancer diagnostics business, which focuses on diagnostic products and services for cancer, including hematologic malignancies. Company updates commonly address performance in the Pathology Services Division and Products Division, customer and laboratory workflow trends, shareholder update calls, and balance sheet actions tied to debt, warrants, and common-stock financing arrangements.
Precipio news also covers its proprietary diagnostic technologies, including the Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, study publications, scientific meeting presentations, and collaborations involving clinical laboratories and cancer centers. Operational disclosures may include cybersecurity response, service continuity, and the company’s use of laboratory-developed technologies that are validated clinically and commercialized for the broader laboratory market.
Precipio (NASDAQ: PRPO) reported a 77% increase in net revenue for Q1-2020, totaling $1.2M, up from $0.7M in Q4-2019. Key drivers included enhanced sales productivity and internalization of molecular tests. Metrics show a 27% rise in pathology revenue, a 43% increase in case volume, and a 56% growth in new customers compared to the prior quarter. However, average revenue per unit decreased 18% from Q4-2019. Management expresses optimism for continued growth despite challenges posed by COVID-19.
Precipio, Inc. (NASDAQ: PRPO) will host its Quarter 1-2020 corporate update call on May 19, 2020, at 5:00 PM ET. Callers can join by dialing 844-695-5519 or internationally at 1-412-902-6760. Registration is available at here, allowing participants to bypass the operator. Precipio aims to improve diagnostic accuracy through collaborations with leading academic institutions, including Yale and Dana-Farber. The call will address questions submitted via email to investors@precipiodx.com. A replay will be accessible 24 hours post-call on the company's investor page.